United Therapeutics Corporation (UTHR) Stock Forecast & Price Target
United Therapeutics Corporation · NASDAQ
$523.47-4.47 (-0.85%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering United Therapeutics Corporation, 9 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $613.00 to $738.00, so the covering firms are broadly aligned. The average target of $685.50 sits 31% above the current $523.47. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 8 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $7.00 next quarter toward $31.51 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Moderate Buy
Strong Buy00%
Buy982%
Hold218%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to United Therapeutics Corporation.
As of Jul, 9 of 11 firms rate UTHR a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
UTHR EPS & revenue forecast
EPS · NEXT QUARTER
$7.00
Range $6.08 – $7.88 · 12 analysts · -2% YoY
Next period, 12 analysts expect United Therapeutics Corporation to earn $7.00 a share (range $6.08 – $7.88), versus $7.16 a year earlier. Full-year consensus is $26.92, growing to $31.51 the year after.
REVENUE · NEXT QUARTER
$818.8M
Range $782.0M – $858.9M · 12 analysts · +2% YoY
Revenue is expected to reach $818.8M (range $782.0M – $858.9M), +2.4% year-over-year. Full-year consensus is $3.2B, rising to $3.7B next year.
Top analysts covering United Therapeutics Corporation
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on UTHR.
#1
Andrew Fein
HC Wainwright & Co. · Rank #35
Buy
$660.00+26.1% to target
Overall win rate
46%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #64
Buy
$687.00+31.2% to target
Overall win rate
52%
+ Follow
#3
Jason Gerberry
B of A Securities · Rank #136
Hold
$626.00+19.6% to target
Overall win rate
46%
+ Follow
#4
LW
Lisa Walter
RBC Capital
Buy
$704.00+34.5% to target
Coverage
—
+ Follow
#5
Roanna Ruiz
SVB Leerink
Buy
No targeton UTHR
Coverage
—
+ Follow
UTHR stock forecast FAQ
What is UTHR's average 12-month price target?+
The 4 analysts with a live target average $685.50 for United Therapeutics Corporation over the next 12 months, ranging from a $738.00 high to a $613.00 low.
Is UTHR stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 11 analyst ratings, 9 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for UTHR?+
The Street-high target is $738.00 (Wells Fargo), and the Street-low is $613.00 (B of A Securities). The average of all 4 active targets is $685.50.
How many Wall Street analysts cover UTHR?+
11 analysts have an active rating on United Therapeutics Corporation, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering UTHR?+
Among analysts who currently cover UTHR, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #35). Their current call is Buy with a $660.00 target.
What is United Therapeutics Corporation's projected EPS for next quarter?+
The consensus estimate is $7.00 per share (range $6.08 – $7.88) across 12 analysts. Full-year EPS is projected at $26.92, rising to $31.51 the following year.
How much revenue is United Therapeutics Corporation expected to report next quarter?+
Consensus revenue is $818.8M (range $782.0M – $858.9M). Full-year revenue is projected at $3.2B, growing to $3.7B next year.
Have analysts been upgrading or downgrading UTHR lately?+
As of Jul, 9 of 11 firms rate UTHR a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their UTHR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
